Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 143,893 | 174,562 | 149,800 | 207,204 | 246,992 |
| Receivables | 81,869 | 64,582 | 51,581 | 49,690 | 35,005 |
| Inventories | 36,272 | 39,422 | 36,628 | 33,688 | 37,898 |
| TOTAL | $304,163 | $302,687 | $271,149 | $330,084 | $331,076 |
| Non-Current Assets | |||||
| PPE Net | 6,035 | 6,451 | 6,754 | 7,196 | 7,670 |
| Intangibles | 145,159 | 154,169 | 167,171 | 172,191 | 181,201 |
| Other Non-Current Assets | 66,447 | 72,049 | 84,273 | 92,796 | 91,916 |
| TOTAL | $217,641 | $232,669 | $258,198 | $272,183 | $280,787 |
| Total Assets | $521,804 | $535,356 | $529,347 | $602,267 | $611,863 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 98,158 | 97,848 | 97,543 | N/A | N/A |
| Accounts payable and accrued liabilities | 24,944 | 19,466 | 33,588 | 28,809 | 41,984 |
| Accrued Expenses | 91,284 | 109,660 | 109,014 | 144,704 | 111,742 |
| Other current liabilities | 14,247 | 16,500 | N/A | N/A | N/A |
| TOTAL | $233,680 | $253,914 | $261,051 | $189,205 | $165,595 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 97,230 | 96,917 |
| Deferred Revenues | 5,047 | 10,440 | 20,906 | 15,692 | 11,869 |
| Other Non-Current Liabilities | 150,795 | 189,970 | 172,814 | 150,717 | 158,122 |
| TOTAL | $225,824 | $255,326 | $194,288 | $275,912 | $271,637 |
| Total Liabilities | $459,504 | $509,240 | $455,339 | $465,117 | $437,232 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 183,849 | 183,533 | 181,231 | 174,960 | 174,538 |
| Common Shares | 2 | 2 | 1 | 2 | 2 |
| Retained earnings | -1,493,496 | -1,522,772 | -1,462,799 | -1,389,673 | -1,330,129 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $62,300 | $26,116 | $74,008 | $137,150 | $174,631 |
| Total Liabilities And Equity | $521,804 | $535,356 | $529,347 | $602,267 | $611,863 |